ABSTRACT
OBJECTIVES: To determine whether excessive alcohol consumption increases the risk for intensive care unit (ICU)-acquired bacterial infection, especially ventilator-associated pneumonia (VAP), in nontrauma patients. DESIGN: Prospective observational cohort study. SETTING: A 21-bed polyvalent ICU in a university hospital. PATIENTS: A total of 358 adult patients admitted over a 1-yr period who had an ICU stay > or = 3 days and in whom alcohol consumption could be assessed. INTERVENTIONS: None. MEASUREMENTS AND MEAN RESULTS: Thirty-one percent of the patients (111 of 358) were identified as at-risk drinkers according to the National Institute on Alcohol Abuse and Alcoholism criteria. Among these, 61 had a daily intake of five or more drinks per day and 73 had Simplified Michigan Alcohol Short Test scores > or = 3. ICU-acquired bacterial infections were diagnosed in 88 patients, and 69 patients had one or more VAPs. Forty (36%) at-risk drinkers acquired bacterial infections vs. 48 (19%) not-at-risk drinkers (p < .001). Among at-risk drinkers, the proportion of patients who developed bacterial infection was higher in at-risk drinkers consuming five or more drinks per day compared with at-risk drinkers consuming fewer than five drinks per day (p = .048). After adjustment for age, gender, Simplified Acute Physiology Score II, length of hospital stay before ICU admission, prior antibiotic administration within 24 hrs before ICU admission, type of admission, immunosuppression, duration of mechanical ventilation, and central venous and urinary catheter exposure, at-risk drinking remained significantly associated with the acquisition of bacterial infection at any site (hazard ratio 1.92; 95% confidence interval, 1.17-3.14; p = .009) and of VAP (hazard ratio 1.76; 95% confidence interval, 1.05-3.06; p = .04). CONCLUSIONS: At-risk drinking was a significant risk factor for acquisition of ICU-acquired bacterial infection.
Subject(s)
Alcoholism/epidemiology , Bacterial Infections/epidemiology , Cross Infection/epidemiology , Intensive Care Units/statistics & numerical data , APACHE , Aged , Alcohol Drinking/adverse effects , Alcohol Drinking/epidemiology , Alcoholism/complications , Alcoholism/mortality , Cohort Studies , Female , France , Hospital Mortality , Humans , Length of Stay/statistics & numerical data , Liver Transplantation/statistics & numerical data , Male , Middle Aged , Pneumonia, Ventilator-Associated/epidemiology , Postoperative Complications/epidemiology , Prospective Studies , Risk , Temperance/statistics & numerical dataABSTRACT
BACKGROUND: The drug (131)I-labeled lipiodol is used as internal radiotherapy for unresectable hepatocellular carcinoma. Although the drug was considered safe during preapproval studies, we observed several cases of interstitial pneumonia following its administration. METHODS: Cases were retrospectively identified through the drug safety unit database of Rennes University Hospital. RESULTS: From 1994 to 2009, interstitial pneumonia developed in 15 patients following (131)I-labeled lipiodol administration, with an estimated prevalence of 15.5 cases (95% CI, 7.7-23.2) per 1,000 treated patients. Mean age of the patients was 60 ± 8 years, and the male to female ratio was 6.5:1. All patients had cirrhosis, mainly related to long-term alcohol intoxication (n = 12). Most (n = 10) cases occurred after the second (131)I-labeled lipiodol injection. The median delay between last (131)I-labeled lipiodol administration and first respiratory symptoms was 30 days (interquartile range, 16.5-45 days). All patients presented with shortness of breath. Physical examination mostly revealed fever (n = 11) and bilateral crackles (n = 12). Chest CT scan showed bilateral ground-glass opacities (n = 8) with septal thickening, retraction, or both (n = 8). BAL (n = 7) was remarkable for increased neutrophils (n = 4) or CD8(+) T cell count (n = 3). Despite corticosteroids, 12 (80%) patients died, mostly of untractable respiratory failure (n = 9). Median delay between last (131)I-labeled lipiodol injection and death was 63 days (interquartile range, 34-129 days). CONCLUSIONS: Interstitial pneumonia may be a serious and not uncommon complication of (131)I-labeled lipiodol administration.
Subject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/drug therapy , Ethiodized Oil/adverse effects , Iodine Radioisotopes/adverse effects , Liver Neoplasms/drug therapy , Lung Diseases, Interstitial/chemically induced , Aged , Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Ethiodized Oil/administration & dosage , Female , Humans , Injections, Intra-Arterial , Iodine Radioisotopes/administration & dosage , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/mortality , Male , Middle Aged , Retrospective Studies , Treatment OutcomeSubject(s)
Endocarditis, Bacterial/surgery , Health Services for the Aged , Aged , Evidence-Based Medicine , HumansABSTRACT
Assay of human chorionic gonadotropin (hCG) is mainly used for the detection and monitoring of pregnancy, and for the follow-up of trophoblastic tumors. The serum free beta-hCG subunit (hCGbeta) is also a tumor marker in many non-trophoblastic tumors, including gastrointestinal cancers. In this work, we compared the performance of several immunoassays for pregnancy exclusion before liver transplantation and in the follow-up of a woman with cholangiocarcinoma. Serum hCG was detected with the Abbott Testpack plus hCG-Combo and measured with four automated sandwich immunoassays: ADVIA-Centaur, ACS:180, AxSYM and Dimension. hCGbeta was determined by an automated fluorescence sandwich immunoassay (Kryptor-Free beta hCG) and with a specific immunoradiometric assay (ELSA-F beta hCG, Schering). The expression of hCG was also evaluated by immunohistochemistry on sections of intrahepatic cholangiocarcinoma cells and on peritoneal metastases. Before transplantation, discordant results were observed for pregnancy exclusion. Qualitative Testpack and Dimension tests detected no hCG-like immunoreactivity, whereas the ADVIA-Centaur, ACS:180 and AxSYM tests revealed positive levels. The same discrepancy was obtained in follow-up of the patient after liver transplantation. hCGbeta assay and immunohistochemical staining revealed tumor cell secretion of hCGbeta. In conclusion, a specific serum immunoassay for intact dimeric hCG without cross-reaction with hCGbeta should be adopted as routine policy for pregnancy exclusion before liver transplantation.
Subject(s)
Cholangiocarcinoma/blood , Chorionic Gonadotropin, beta Subunit, Human/blood , Chorionic Gonadotropin/blood , Chorionic Gonadotropin/chemistry , Liver Neoplasms/blood , Pregnancy/blood , Adult , Blood Chemical Analysis/methods , Blood Chemical Analysis/statistics & numerical data , Cholangiocarcinoma/complications , Cholangiocarcinoma/metabolism , Cholangiocarcinoma/surgery , Chorionic Gonadotropin/metabolism , Chorionic Gonadotropin, beta Subunit, Human/chemistry , Chorionic Gonadotropin, beta Subunit, Human/metabolism , Dimerization , False Positive Reactions , Female , Humans , Immunoassay/methods , Immunoassay/statistics & numerical data , Immunohistochemistry , Liver Neoplasms/complications , Liver Neoplasms/metabolism , Liver Neoplasms/surgery , Liver Transplantation , Pregnancy Complications, Neoplastic/blood , Pregnancy Complications, Neoplastic/metabolism , Sensitivity and SpecificityABSTRACT
The most common causes of exudative pleural effusion are tuberculosis, malignancy, and pneumonia. However, exudative pleural effusion may also reveal contiguous infectious processes including cholecystitis, subphrenic pus collection, and thoracic vertebral osteomyelitis. In the latter, the diagnosis is usually delayed. We report two cases of thoracic vertebral osteomyelitis presenting as exudative pleural effusion for which the diagnosis could be suspected by a careful analysis of the thoracic imaging studies performed on admission.